Wolfe Research Initiates Coverage On Mirum Pharmaceuticals with Outperform Rating, Announces Price Target of $145
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wolfe Research analyst Kalpit Patel initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform rating and announces Price Target of $145.
Wolfe Research analyst Kalpit Patel initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform rating and announces Price Target of $145.